Novel antidiabetic therapies in patients with peripheral artery disease: current perspective.
作者信息
Janić Miodrag, Maggio Viviana, Janež Andrej, Rizzo Manfredi
机构信息
Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
出版信息
Front Clin Diabetes Healthc. 2024 Nov 26;5:1517265. doi: 10.3389/fcdhc.2024.1517265. eCollection 2024.
Abstract
摘要
相似文献
1
Novel antidiabetic therapies in patients with peripheral artery disease: current perspective.外周动脉疾病患者的新型抗糖尿病疗法：当前观点
Front Clin Diabetes Healthc. 2024 Nov 26;5:1517265. doi: 10.3389/fcdhc.2024.1517265. eCollection 2024.
2
Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.药物治疗 2 型糖尿病的获益与危害：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2023 Apr 6;381:e074068. doi: 10.1136/bmj-2022-074068.
3
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
4
Efficacy and safety of the combination or monotherapy with GLP-1 receptor agonists and SGLT-2 inhibitors in Type 2 diabetes mellitus: An update systematic review and meta-analysis.GLP-1 受体激动剂和 SGLT-2 抑制剂联合或单药治疗 2 型糖尿病的疗效和安全性：更新的系统评价和荟萃分析。
Am J Med Sci. 2024 Dec;368(6):579-588. doi: 10.1016/j.amjms.2024.07.011. Epub 2024 Jul 6.
5
Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.与 GLP-1 受体激动剂相比，SGLT-2 抑制剂在 2 型糖尿病中的心血管和其他糖尿病相关结局：全国性观察性研究。
Cardiovasc Diabetol. 2021 Mar 22;20(1):67. doi: 10.1186/s12933-021-01258-x.
6
SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.在临床实践中，钠-葡萄糖协同转运蛋白 2 抑制剂、胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂与 2 型糖尿病患者高钾血症风险的关系：基于人群的队列研究。
BMJ. 2024 Jun 26;385:e078483. doi: 10.1136/bmj-2023-078483.
7
An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors.GLP-1 受体激动剂和 SGLT-2 抑制剂心血管结局试验的更新视角和汇总分析。
Anatol J Cardiol. 2021 Feb;25(2):61-76. doi: 10.14744/AnatolJCardiol.2020.06630.
8
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.
9
Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials.抗糖尿病药物对肾脏和心血管结局的多效作用：随机对照试验的荟萃分析。
Int Urol Nephrol. 2020 Sep;52(9):1733-1745. doi: 10.1007/s11255-020-02520-z. Epub 2020 Jun 10.
10
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.SGLT-2 抑制剂与 GLP-1 受体激动剂在 2 型糖尿病合并慢性肾脏病患者中的心血管和肾脏结局：系统评价和网络荟萃分析。
Cardiovasc Diabetol. 2021 Jan 7;20(1):14. doi: 10.1186/s12933-020-01197-z.
引用本文的文献
1
Role of Residual Inflammation as a Risk Factor Across Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Unpacking the Burden in People with Type 2 Diabetes.残余炎症作为心血管-肾脏-代谢（CKM）综合征危险因素的作用：剖析2型糖尿病患者的负担
Diabetes Ther. 2025 May 9. doi: 10.1007/s13300-025-01743-6.
2
Physical activity levels among long-term cancer survivors of more than 5 years: a propensity score matching analysis.5年以上癌症长期幸存者的身体活动水平：一项倾向评分匹配分析。
Support Care Cancer. 2025 Apr 2;33(4):340. doi: 10.1007/s00520-025-09366-0.
本文引用的文献
1
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases.2024年欧洲心脏病学会外周动脉和主动脉疾病管理指南
Eur Heart J. 2024 Sep 29;45(36):3538-3700. doi: 10.1093/eurheartj/ehae179.
2
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group.心脏代谢连续体的现代管理：从超重/肥胖到糖尿病前期/2型糖尿病。东欧和南欧糖尿病与肥胖专家组的建议。
Diabetes Ther. 2024 Sep;15(9):1865-1892. doi: 10.1007/s13300-024-01615-5. Epub 2024 Jul 11.
3
Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review.下肢外周动脉疾病患者 2 型糖尿病管理中的挑战与机遇：量身定制的诊断和治疗回顾。
Cardiovasc Diabetol. 2024 Jun 26;23(1):220. doi: 10.1186/s12933-024-02325-9.
4
Medical Therapy for Peripheral Artery Disease.外周动脉疾病的医学治疗。
Curr Cardiol Rep. 2024 Jun;26(6):651-659. doi: 10.1007/s11886-024-02065-y. Epub 2024 May 2.
5
Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: The STARDUST Randomized Clinical Trial.利拉鲁肽用于2型糖尿病合并外周动脉疾病患者的下肢灌注：STARDUST随机临床试验
JAMA Netw Open. 2024 Mar 4;7(3):e241545. doi: 10.1001/jamanetworkopen.2024.1545.
6
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
7
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.在 2 型糖尿病合并动脉粥样硬化性心血管疾病患者中比较替西帕肽与度拉糖肽对主要不良心血管事件的影响：SURPASS-CVOT 设计与基线特征。
Am Heart J. 2024 Jan;267:1-11. doi: 10.1016/j.ahj.2023.09.007. Epub 2023 Sep 25.
8
The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer.国际血管外科学会联合会、欧洲血管外科学会、血管外科学会关于糖尿病合并足部溃疡患者外周动脉疾病的指南。
Diabetes Metab Res Rev. 2024 Mar;40(3):e3686. doi: 10.1002/dmrr.3686. Epub 2023 Sep 19.
9
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.2023年欧洲心脏病学会糖尿病患者心血管疾病管理指南
Eur Heart J. 2023 Oct 14;44(39):4043-4140. doi: 10.1093/eurheartj/ehad192.
10
Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials.司美格鲁肽与其他胰高血糖素样肽-1 受体激动剂对 2 型糖尿病患者心代谢风险因素的影响：头对头、3 期、随机对照试验的系统评价和荟萃分析。
J Diabetes Complications. 2023 Aug;37(8):108529. doi: 10.1016/j.jdiacomp.2023.108529. Epub 2023 Jun 7.
Zotero 插件